Special premium report Part 1: My 2018 earnings boom profit strategy–and two picks
With the report of first quarter earnings season from Netflix (NFLX) on Monday, April 16, we’ve moved into the heart of earnings season. In most quarters traders began putting on plays for earnings announcements a few weeks before reporting starts. And they’ll keep making new bets over the next three weeks or so. In most quarters buying shares or options on companies about to report makes profitable sense. But this strategy is likely to be even more rewarding this year
Monday buy of SolarEdge Technologies in my Jubak Picks portfolio
I've been looking for a way out of this investing puzzle for a while and I think I've finally found one. SolarEdge Technologies (SEDG). I'm adding these shares to my Jubak Picks Portfolio on Monday. And I'll be buying call options on these shares in my Volatility...
New calculation: Current cash position in Jubak Picks Portfolio
In response to reader requests from here on out I’m going to calculate an approximate cash position (I won’t do all the nitty gritty to include things like the latest dividend payouts but the number should be reasonably close) after each buy and sell. The latest action in the portfolio was the April 3, 2018 sell of Freeport McMoRan Copper & Gold. After that sale the cash position in the portfolio is 31.6%. That’s up from 27.2% at the end of December 2017.
Selling copper pick Freeport McMoran on fears of U.S./China tariff war
Freeport McMoRan Copper and Gold (FCX) was the third and last copper stock I added to my portfolios back in January 12, 2018--after Southern Copper (SCCO) and First Quantum Minerals (FQMLF). I added so much copper since copper prices were soaring in 2017--up 30%--and...
Little spillover (yet) from Concho acquisition of Permian producer RSPP
Today Concho Resources (CXO) announced the acquisition of RSP Permian (RSPP) to create the biggest  oil and natural gas producer from the shales of the Permian Basin. The $9.5 billion all stock deal represents a 29% premium to the Tuesday close for RSP Permian. That...
Turning around the Jubak Picks portfolio: It takes time (frustrating amounts of time) but by late 2016 the recovery was in place: 2017 total return 13.13% despite 27.2% cash
Turning around a portfolio can take a frustratingly long time. The Jubak’s Picks portfolio has had a performance problem since 2014. But I think I’ve finally put a recovery in place. The total return on the portfolio was 13.1% in 2017. That still badly lagged the 21.7% total return on the Standard & Poor’s 500. But it’s promising–considering that the portfolio finished the year 27.2% in cash. (Which itself was better than the 37% cash at the end of 2016.)
FDA sets next date for Incyte arthritis drug, baricitinib
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis
Selling Acadia Pharmaceuticals out of my Jubak Picks portfolio
Today I'm selling Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio. I have a 13.52% loss on this position since I added the shares to the portfolio on November 15, 2016. There are short- and long-range reasons to sell. From a short-range perspective for...
Bristol-Myers puts up potential $3.6 billion in deal for 35% of a Nektar cancer drug
In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate still in trials and that has shown the ability to extend the range of Bristol-Myers Opdivo
Autoliv earnings beat and spinoff plans buck today’s market plunge
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Caterpillar beats on earnings and guidance but stock falls 1.4% today
Investors and traders were determined to sell Caterpillar (CAT) shares after the stock gained 70% in 2017. That determination overshadowed yesterday's good news on fourth quarter earnings and positive guidance for 2018. The shares, which I added to my Jubak Picks...Jim’s Stock Alerts
Download Jim’s eBook for Free
